STOCK TITAN

Syros Pharmaceuticals Inc. - SYRS STOCK NEWS

Welcome to our dedicated news page for Syros Pharmaceuticals (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Syros Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Syros Pharmaceuticals's position in the market.

Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ: SYRS) reported financial results and provided a corporate update. The company is on track to report initial data from the SELECT-AML-1 trial in early December 2023 and pivotal CR data from SELECT-MDS-1 by mid-4Q 2024. Founding CEO, Nancy Simonian, M.D., will retire, and Conley Chee will succeed as CEO. The company is focused on advancing tamibarotene for the frontline treatment of hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
-
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ:SYRS) will host a conference call and webcast on November 14, 2023, to report its third quarter 2023 financial results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
conferences earnings
-
Rhea-AI Summary
Syros Pharmaceuticals announces strategic realignment to prioritize development of tamibarotene for HR-MDS and AML. Workforce reduction of approximately 35% implemented. Conley Chee appointed as CEO, effective December 2, 2023. Nancy Simonian to retire as CEO and remain on the Board of Directors. Tamibarotene has potential to set new standard of care for RARA overexpression patients. Company will stop further investment in SY-2101 development. Eric Olson, Chief Scientific Officer, to depart effective October 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.73%
Tags
management
Rhea-AI Summary
Syros Pharmaceuticals grants 20,650 restricted stock units (RSUs) to new employees as inducement to employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
Rhea-AI Summary
Syros Pharmaceuticals (SYRS) reports financial results and corporate update, on track to announce initial randomized data from SELECT-AML-1 trial in 4Q 2023 and complete enrollment of 190 patients in SELECT-MDS-1 trial in 4Q 2023 with pivotal CR data expected in 3Q 2024. Second Quarter 2023 financial results show a net loss of $36.3 million, cash and financial guidance into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
conferences earnings
-
Rhea-AI Summary
Syros Pharmaceuticals (NASDAQ:SYRS) has granted a restricted stock unit (RSU) award of 9,000 shares of Syros common stock to a newly hired employee. The RSU was granted as a material inducement to employment and will vest over a period of four years, subject to the employee's continued service with Syros.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Syros Pharmaceuticals Inc.

Nasdaq:SYRS

SYRS Rankings

SYRS Stock Data

142.59M
11.26M
1.08%
81.44%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SYRS

syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.